

Product Name: SB 204990

Catalog No.: 4962


Batch No.: 2

CAS Number: 154566-12-8

IUPAC Name: (3R,5S)-rel-5-[6-(2,4-Dichlorophenyl)hexyl]tetrahydro-3-hydroxy-2-oxo-3-furanacetic acid

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula: C₁₈H₂₂Cl₂O₅
Batch Molecular Weight: 389.27
Physical Appearance: White solid
Solubility: DMSO to 100 mM
 ethanol to 100 mM
Storage: Store at -20°C
Batch Molecular Structure:



2. ANALYTICAL DATA

TLC: R_f = 0.4 (Dichloromethane:Methanol [9:1])
HPLC: Shows 98.1% purity
¹H NMR: Consistent with structure
Mass Spectrum: Consistent with structure
Microanalysis:

	Carbon	Hydrogen	Nitrogen
Theoretical	55.54	5.7	
Found	55.74	5.82	0.1

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

Product Name: SB 204990

Catalog No.: 4962

2

CAS Number: 154566-12-8

IUPAC Name: (3R,5S)-rel-5-[6-(2,4-Dichlorophenyl)hexyl]tetrahydro-3-hydroxy-2-oxo-3-furanacetic acid

Description:

SB 204990 is an ATP citrate lyase (ACLY) inhibitor; it is a prodrug of SB 201076. SB 204990 inhibits cholesterol and fatty acid synthesis in a dose-dependent manner in HepG2 cells. Suppresses growth of cancer cells showing aerobic glycolysis in vitro and in vivo. Orally active.

Physical and Chemical Properties:


Batch Molecular Formula: C₁₈H₂₂Cl₂O₅

Batch Molecular Weight: 389.27

Physical Appearance: White solid

Minimum Purity: ≥98%

Batch Molecular Structure:



Storage: Store at -20°C

Solubility & Usage Info:

DMSO to 100 mM
ethanol to 100 mM

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

Licensing Information:

Sold for research purposes under agreement from GlaxoSmithKline

References:

Hatzivassiliou et al (2005) ATP citrate lyase inhibition can suppress tumor cell growth. *Cancer Cell* **8** 311. PMID: 16226706.

Gribble et al (1998) ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R*,5S*)-ω-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzy J.Med.Chem. **41** 3582. PMID: 9733484.

Pearce et al (1998) The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. *Biochem.J.* **334** 113. PMID: 9693110.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

bio-techne.com

info@bio-techne.com
techsupport@bio-techne.com

North America

Tel: (800) 343 7475

China

info.cn@bio-techne.com
Tel: +86 (21) 52380373

Europe Middle East Africa

Tel: +44 (0)1235 529449

Rest of World

www.tocris.com/distributors
Tel:+1 612 379 2956